NCT06206395

Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients

Assiut University-Egypt

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 190 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The field of oncology has advanced remarkably. Some of the old and new emerging cancer therapies are associated with development of cardiovascular toxicities , which may have the potential to offset the gains in survival obtained with this cancer treatment advances. Much of the focus on cardiovascular toxicities has been in the early detection of myocardial damage and prediction of cancer therapeutics-related cardiac dysfunction (CTRCD). The main strategy for these patients is timely diagnosis and treatment of high-risk individual Cardiac dysfunction associated with cancer treatment is the main cause of mortality in cancer survivors. The mortality rate is recorded to be up to 60% in the first two years after therapy. The most commonly associated drugs with cardiotoxicity are anthracycline (AC) and monoclonal antibodies (such as trastuzumab). Other new agents, such as vascular endothelial growth factor (VEGF) inhibitors, immunotherapies, and proteasome inhibitors, can also cause cardiac dysfunction .

Conditions

• 2D Speckle Tracking Echocardiography
• Breast Cancer
• Cardiac Magnetic Resonance

Interventions

Type	Name	Description
DEVICE	Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging	2D speckle tracking echo will be performed before chemotherapy and after mid-cycle and after completion of treatment. 3D echo and CMR will be performed before and after chemotherapy treatment.

Timeline

• Start date: 2024-02-01
• Primary completion: 2025-03-01
• Completion: 2025-05-01
• First posted: 2024-01-16
• Last updated: 2024-01-16

Locations

1 site across 1 country: Egypt